Prepubertal testicular cancer found to be rare in U.S.

NewsGuard 100/100 Score

It has been reported that the incidence of testicular cancer in the Caucasian population in the United States increased during most of the last half of the 20th Century, but information on trends in the occurrence of prepubertal testicular cancer is lacking in the literature.

Walsh, et al, from Seattle, Washington analyzed the population-based cohort to determine whether the incidence trends of prepubertal testicular germ cell tumors have risen similarly to those seen in the adult testicular tumors. They identified cases of histological confirmed germ cell cancer in boys from the newborn period to 14 years of age, of all races, over a period from 1973-2000. They performed a study the Surveillance, Epidemiology, and End Results program of the National Cancer Institute. The variable analyzed included age, race, tumor histological type, and year of diagnosis.

The group found that a total of 131 cases of germ cell cancer were diagnosed among boys of all races, with an overall incidence of 1.6 cases per 1 million person-years. Yolk sac tumor was the most common, followed by teratoma. Choriocarcinoma and seminoma were equally rare. Tumors were most common among Caucasians during early infancy. No secular trends in incidence rates were identified.

The group concluded that prepubertal testicular cancer is rare. All tumors were more common in Caucasians. In contrast to adult testicular cancer, no clear trend over time was found for prepubertal tumors. Whatever the etiology may be for the increased incidence of testicular cancer over time in men, it does not seem to apply to testicular cancer in boys.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA approval of Anktiva heralds a new era in the treatment of BCG-unresponsive non–muscle-invasive bladder cancer